Barts-MS rose-tinted-odometer: ★
I did a post a few weeks ago about the secondary malignancy risk associated with longterm continuous immunosuppression and included a survey. The following are the results of the survey, which are quite disturbing. It is clear that a significant number of readers of this blog, although aware of the secondary cancer risk, are not been given standardised information about cancer risk and cancer screening. This is another piece of work that needs to be done and done well. Some of the comments are quite telling as well, including some personal critcism.
Who is interested in working on an evidence-based calculator of secondary malignancy risk in relation to MS DMTs? It will at least need to include the following variables:
- Family history
- Environmental risk factors, e.g. sun exposure, HPV vaccination status
- Type of immunosuppression, i.e. continuous (anti-CD20, S1P modulators) vs. short-term (alemtuzumab, cladribine)
- Intensity of immunosuppression
- Duration of immunosuppression
- Prior treatment history
- Prior cancer history
I suspect many health and life insurance companies have actuarial data on this already and could potentially create a risk calculator using real-life data.
Would you use such a calculator? Comments please.